Recent Quotes
My Watchlist
Indicators
Local Stocks
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nutriband Inc. - Common Stock (NQ: NTRB )

7.150 -0.660 (-8.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nutriband Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
The AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents already issued in 46 countries including the United States, Europe,... 
From Nutriband Inc.
Via GlobeNewswire
Nutriband Issues Letter to Shareholders
From Nutriband Inc.
Via GlobeNewswire
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
From Nutriband Inc.
Via GlobeNewswire
Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica
Via ACCESSWIRE
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
From Nutriband Inc.
Via GlobeNewswire
Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4th
From Nutriband Inc.
Via GlobeNewswire
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology
AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch 
From Nutriband Inc.
Via GlobeNewswire
Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application
Via ACCESSWIRE
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session
Via Investor Brand Network
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17
Via ACCESSWIRE
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
NUTRIBAND RECEIVES CHINA PATENT NOTICE OF ALLOWANCE FOR ITS AVERSA™ ABUSE DETERRENT TRANSDERMAL TECHNOLOGY
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for a patent application covering its Nutriband AVERSA™ abuse deterrent transdermal technology Nutriband... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
Via ACCESSWIRE
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product
Via Investor Brand Network
Women Reach Settlement After Yale Nurse Switched Painkillers with Saline Solution
Via Investor Brand Network
Topics Lawsuit
Exposures Financial Legal
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
Via ACCESSWIRE
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Reports on Share Repurchase Program
Via Investor Brand Network
Nutriband Inc. Authorizes $1M Share Buyback Program
Via ACCESSWIRE
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Releases Q2 Report, AVERSA Fentanyl Update
Via Investor Brand Network
Exposures Product Safety
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
Via ACCESSWIRE
Proposed US Law Would Direct Opioid Settlement Cash to Opioid Crisis Management
Via Investor Brand Network
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Execs to Participate in July 25 Investor Webinar
Via Investor Brand Network
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25
Via ACCESSWIRE
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
Via ACCESSWIRE
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Shares Update on Its AVERSA(TM) Fentanyl Product Development Program
Via Investor Brand Network
Exposures Product Safety
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
Via ACCESSWIRE
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Releases Q1 2024 Quarterly Report
Via Investor Brand Network
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.